^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | telaglenastat (CB-839) (Glutaminase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome
Excerpt:
...Subjects with high-risk MDS (i.e. International Prognostic Scoring System [IPSS] Intermediate-2 or high-risk; or R-IPSS high or very-high risk). Patients with Intermediate-1 risk by IPSS or Intermediate risk by R-IPSS and with IDH1 or IDH2, or high-risk molecular features including TP53, ASXL1, EZH2, and/or RUNX1 mutations are also eligible...
Trial ID:
Source:
Title:
1281 AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis
Published date:
11/04/2020
Excerpt:
This is a single arm phase Ib/II trial of CB-839 in combination with azacitidine (AZA) for patients with intermediate and high-risk MDS….Patients with TP53 mutations had CR/mCR rate of 62.5% (5/8) and mOS of 8 months….CB-839 in combination with AZA is a safe and effective regimen for patients with advanced MDS.
Secondary therapy:
azacitidine
Trial ID:
